GlassScriptPhysician profile
Mary Lane
NPI 1437596301
$7,793.40
in general payments reported to CMS, 2019-2025
21 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $694 · 2022: $631 · 2023: $1,098 · 2024: $3,700 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Consulting Fee: $1,428 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.23 |
| Consulting Fee | $1,427.50 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,584.28 | 2021-2025 | Opdivo, Onureg, Reblozyl |
| Glaxosmithkline, LLC. | $1,409.57 | 2023-2024 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $1,300.66 | 2021-2025 | Carvykti, Rybrevant, Erleada |
| Fresenius Kabi USA, LLC | $582.34 | 2024 | Stimufend |
| Astellas Pharma US INC | $421.99 | 2024-2025 | Vyloy, Xospata |
| Abbvie INC. | $319.88 | 2024-2025 | |
| Eisai INC. | $308.91 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.43 | 2022-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $220.34 | 2023-2024 | Lynparza |
| Regeneron Healthcare Solutions, INC. | $175.11 | 2025 | Libtayo |
| Adaptive Biotechnologies Corporation | $162.88 | 2025 | Clonoseq |
| Beone Medicines USA, INC. | $133.08 | 2025 | Tevimbra |
| Agios Pharmaceuticals, INC. | $121.72 | 2024 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $120.62 | 2025 | Givlaari |
| Gilead Sciences, INC. | $120.09 | 2021-2024 | Trodelvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.39 | 2024 | |
| Beigene USA, INC. | $113.62 | 2023-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $112.77 | 2021 | |
| Daiichi Sankyo INC. | $83.51 | 2022 | |
| Stemline Therapeutics INC. | $83.33 | 2024 | Orserdu |
| Incyte Corporation | $48.88 | 2023 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.